Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TIL (Tumor Infiltrating Lymphocytes) and IL2 (Interleukin 2) Versus Abstention as Adjuvant Treatment in Melanoma With Only One Invaded Lymphnode After Lymphnodes Excision

NCT00200577 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT00200577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00200577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TIL (Tumor Infiltrating Lymphocytes) and IL2 (Interleukin 2) Versus Abstention as Adjuvant Treatment in Melanoma With Only One Invaded Lymphnode After Lymphnodes Excision
Lead sponsor
Nantes University Hospital
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
March 31, 2012
Enrollment
70 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma